Datascope posts revenue growth in fiscal 2Q
Increased sales of bedside monitors, including two new product introductions, powered Datascope Corp. to greater revenues in its second fiscal quarter, ending Dec. 31, 2003.
Sales increased 5 percent to $86.8 million, compared with $82.5 million in the second quarter of FY03. Favorable foreign exchange rates accounted for $2 million of that increase. Net earnings slipped to $5.6 million, compared with $7 million in the year-ago quarter. Earnings in the second quarter of FY04 benefited by an after-tax gain of $1.9 million from the settlement of patent litigation.
For the six-month period, revenues rose 6 percent to $163.9 million, compared with $154.5 million in the first half of FY03. The company noted that favorable foreign exchange rates contributed $3.2 million to that increase. Net earnings were $9.8 million, compared with $10.7 million in the year-ago period.
For the 12th straight quarter, sales of patient monitoring products exceeded sales of the prior year's quarter, rising 10 percent to a record $38.6 million. Increased sales of bedside monitors, including sales of the recently introduced Spectrum and Trio monitors, accounted for the growth.
Sales increased 5 percent to $86.8 million, compared with $82.5 million in the second quarter of FY03. Favorable foreign exchange rates accounted for $2 million of that increase. Net earnings slipped to $5.6 million, compared with $7 million in the year-ago quarter. Earnings in the second quarter of FY04 benefited by an after-tax gain of $1.9 million from the settlement of patent litigation.
For the six-month period, revenues rose 6 percent to $163.9 million, compared with $154.5 million in the first half of FY03. The company noted that favorable foreign exchange rates contributed $3.2 million to that increase. Net earnings were $9.8 million, compared with $10.7 million in the year-ago period.
For the 12th straight quarter, sales of patient monitoring products exceeded sales of the prior year's quarter, rising 10 percent to a record $38.6 million. Increased sales of bedside monitors, including sales of the recently introduced Spectrum and Trio monitors, accounted for the growth.